首页|玻璃体腔注射雷珠单抗对增殖性糖尿病性视网膜病变患者视力及血清GAS6、SDF-1及VEGF的影响

玻璃体腔注射雷珠单抗对增殖性糖尿病性视网膜病变患者视力及血清GAS6、SDF-1及VEGF的影响

扫码查看
目的 探讨增殖性糖尿病视网膜病变(PDR)给予玻璃体腔注射雷珠单抗药物对患者视力以及血清人生长停滞特异性蛋白(GAS6)、人基质细胞衍生因子1(SDF-1)、血管内皮细胞生长因子(VEGF)影响.方法 纳入2022年1月至12月收治的PDR患者82例,按照随机数字表法分为观察组和对照组,每组41例.对照组采用玻璃体切割术(PPV)治疗,观察组采用联合玻璃体切割术(PPV)术前经玻璃体腔注射雷珠单抗治疗.对比2组的治疗效果,2组患者术前与术后1周的视力以及眼压水平,2组患者术前与术后1周血清GAS6、SDF-1、VEGF水平变化,2组术后并发症发生情况.结果 观察组治疗总有效率为95.12%高于对照组的78.05%(P<0.05).2组患者术后1周的眼压、血清GAS6、SDF-1、VEGF水平均较术前降低,且观察组术后1周的上述指标水平低于对照组(P<0.05).2组术后1周视力较术前升高,且观察组视力水平高于对照组(P<0.05).观察组患者术后并发症总发生率为4.88%低于对照组的24.39%(P<0.05).结论 应用玻璃体腔注射雷珠单抗辅助PPV治疗PDR,效果满意,可显著提高患者视力,降低眼压,降低血清GAS6、SDF-1、VEGF水平,且术后并发症发生率低,值得推广.
Effects of intravitreal injection of leizumab on visual acuity,serum GAS6,SDF-1 and VEGF in patients with proliferative diabetic retinopathy
Objective To investigate the effects of intravitreal injection of leizumab on visual acuity,serum growth arrest-specific protein 6(GAS6),human stromal cell-derived factor-1(SDF-1)and vascular endothelial growth factor(VEGF)in patients with proliferative diabetic retinopathy(PDR).Methods A total of 82 patients with PDR admitted to our hospital from January to December 2022 were included,and they were divided into observation group(n=41)and control group(n=41)by a random number table.The patients in the control group were treated with pars plana vitrectomy(PPV),while those in the observation group were additionally treated with preoperative intravitreal injection of leizumab before PPV.The therapeutic effects of the two groups were compared,including the visual acuity and intraocular pressure of the two groups before and 1 week after surgery,the changes in serum GAS6,SDF-1 and VEGF levels between the two groups before surgery and 1 week after surgery,and the occurrence of postoperative complications between the two groups.Results The total effective rate of observation group was significantly higher than that of control group(95.12%vs 78.05%,P<0.05).The levels of intraocular pressure,serum GAS6,SDF-1 and VEGF 1 week after surgery in the both groups were significantly decreased than those before surgery,which in observation group were significantly lower than those of control group(P<0.05).The visual acuity on 1 week after surgery of the two groups was significantly higher than that before surgery,and which was significantly higher in the observation group than in the control group on 1 week after surgery(P<0.05).The total incidence of postoperative complications in observation group was significantly lower than that of control group(4.88%vs 24.39%,P<0.05).Conclusion The intravitreal injection of leizumab assisted PPV in the treatment of PDR has satisfactory effects,which can significantly improve the visual acuity of patients,and reduce intraocular pressure.In addition,it is capable to reduce serum levels of GAS6,SDF-1 and VEGF,and the incidence of postoperative complications.It is worth of promotion.

proliferative diabetic retinopathyleizumabintravitreal injectionvisual acuitygrowth arrest-specific protein 6human stromal cell derived factor 1vascular endothelial growth factor

张赢赢、王卉、张倩倩、孟娇、褚战亚

展开 >

050000 河北省石家庄市人民医院眼科

增殖性糖尿病性视网膜病变 雷珠单抗 玻璃体腔注射 视力 人生长停滞特异性蛋白 人基质细胞衍生因子1 血管内皮细胞生长因子

河北省医学科学研究课题计划

20210807

2024

河北医药
河北省医学情报研究所

河北医药

CSTPCD
影响因子:1.075
ISSN:1002-7386
年,卷(期):2024.46(13)
  • 13